Metastasis via the lymphatics is a major risk factor in squamous cell carcinoma of the oral cavity (OSCC). We sought to determine whether the presence of metastasis in the regional lymph node could be predicted by a gene expression signature of the primary tumor. A total of 18 OSCCs were characterized for gene expression by hybridizing RNA to Affymetrix U133A gene chips. Genes with differential expression were identified using a permutation technique and verified by quantitative RT-PCR and immunohistochemistry. A predictive rule was built using a support vector machine, and the accuracy of the rule was evaluated using crossvalidation on the original data set and prediction of an independent set of four patients. Metastatic primary tumors could be differentiated from nonmetastatic primary tumors by a signature gene set of 116 genes. This signature gene set correctly predicted the four independent patients as well as associating five lymph node metastases from the original patient set with the metastatic primary tumor group. We concluded that lymph node metastasis could be predicted by gene expression profiles of primary oral cavity squamous cell carcinomas. The presence of a gene expression signature for lymph node metastasis indicates that clinical testing to assess risk for lymph node metastasis should be possible.
Introduction
Metastasis, the dissemination of tumor cells that colonize new areas of the body, may progress via the bloodstream or the lymphatics. Head and neck squamous cell carcinoma (HNSCC) characteristically metastasizes to the regional lymph nodes through the draining lymphatics. We focused on HNSCC originating in the oral cavity (OSCC). Typically, 50% of patients with OSCC have detectable lymph node involvement at presentation. Metastasis to distant sites is relatively uncommon, occurring in less than 5% at presentation. Patients with lymph node metastasis have a markedly worse prognosis than patients without metastasis. Only 25-40% of patients with lymph node metastasis at presentation will achieve 5-year survival, compared to approximately 90% of patients without metastasis (Hong and Weber, 1995; Greenberg et al., 2003) . Some of the patients without lymph node metastasis at presentation will subsequently manifest metastasis. Since removal of lymph nodes and/or radiation and chemotherapy can reduce emergence of occult metastasis, attempts to predict the patients in this category are made clinically (Kim et al., 1993; Myers et al., 1998) . Currently, node-negative patients estimated to have a 20% or greater risk of metastasis often have surgical removal of draining lymph nodes and radiation. The ability to better predict lymph node metastasis could allow therapy better tailored to each patient.
The pioneering studies of metastasis by Fidler and Kripke (1977) established that a primary tumor is composed of cells with widely differing metastatic potentials. This concept of tumor heterogeneity might predict that studying the bulk tumor would not be useful in predicting metastasis, since a large number of poorly metastatic cells might obscure the properties of a small number of highly metastatic cells (Poste and Fidler, 1980) . However, gene signatures have been identified in several tumor types which correlate primary tumor gene expression with increased risk of metastasis Kikuchi et al., 2003; Ramaswamy et al., 2003; Weiss et al., 2003; Bertucci et al., 2004; Nakamura et al., 2004) . These data are part of an increasing body of work indicating that the genetic signature of the majority of cells in a primary tumor holds significant value. Differences in gene expression between metastatic and nonmetastatic primary tumors may expose patterns of metastatic potential and could serve as a basis for clinical testing for metastatic potential at biopsy.
Metastasis research has focused largely on hematogenous metastasis although spread through the lymphatics is common in many cancers. Recent data indicate that the processes of hematogenous and lymphatic metastasis are markedly different . Studies in breast, lung, colon, and pancreatic cancer have begun to address the issue of lymphatic metastasis, but these diseases are also prone to the confounding factor of distant metastasis (West et al., 2001; Kikuchi et al., 2003; Bertucci et al., 2004; Nakamura et al., 2004) . HNSCC may be a useful system for studying lymphatic metastasis because of the high probability of lymphatic spread and low probability of hematogenous spread. A recent study has identified a gene signature for recurrent disease in HNSCC and several studies have investigated the changes in gene expression from normal tissue to carcinoma, but studies involving lymphatic metastasis have been limited by the small number of genes assessed and/or lack of a rigorous efficacy test of the metastatic signature (Alevizos et al., 2001; Belbin et al., 2002; Mendez et al., 2002; Hwang et al., 2003; Gonzalez et al., 2003; Leethanakul et al., 2003; Nagata et al., 2003; Chung et al., 2004; Ginos et al., 2004; Schmalbach et al., 2004; Warner et al., 2004) .
We designed our experiment to investigate whether differences in gene expression between N þ and NÀ primary tumor groups could be used to predict the N status of an independent patient set, and whether such a discriminatory gene signature would be similar to those predicting hematogenous metastasis.
Results
We compared the gene expression profiles obtained from primary squamous cell carcinomas of the oral cavity (OSCC) that were metastatic to lymph nodes (N þ ) to those that were not (NÀ). Tumor samples were collected from 18 patients undergoing surgical treatment for OSCC. Samples from lymph node metastases were obtained from five patients. An additional four primary tumor samples were obtained independently for use as a microarray test set, and three primary and two lymph node samples were obtained for immunohistochemical validation. The clinical characteristics of these patients are outlined in Figure 1 . Total RNA was isolated from tissue samples shown by frozen section to be devoid of normal tissue. Probes generated from this RNA were hybridized to Affymetrix U133A genechips.
Application of the permutation-based method Significance Analysis of Microarrays (SAM) to the signal data identified 147 differentially expressed transcripts with an estimated median false discovery rate of 6.1%. The differences in transcript levels found by hybridization to the Affymetrix chip were confirmed by quantitative real-time RT-PCR. We compared the average values of the N þ patients to the average values of the NÀ patients for four genes: hypothetical protein MGC3731 and keratin 13 from the list of genes generated by SAM, and BAG1 and RPB6, whose Affymetrix signals were significantly different between N þ and NÀ using a two-sided t-test but which were not present in the SAM-generated list. The direction of change for all four genes using quantitative real-time PCR corresponded with the direction of change from the microarrays (data not shown). Figure 1 Clinical features of patients in study. A total of 18 were included in the original test group, four patients compose the microarray validation set, and three compose the supplemental immunohistochemistry set
The set of genes selected by SAM was modified by removing genes whose expression levels were below background in both N þ and NÀ groups. The resulting signature set of 116 genes ( Figure 2b and Supplementary Figure 1 ) was evaluated for its ability to discriminate between metastatic and nonmetastatic primary tumors. As expected, hierarchical clustering using the signature set showed that all metastatic primary tumors clustered together, and all nonmetastatic primary tumors with one exception (patient 16, which exhibits features of both groups) clustered together ( Figure 2a) .
The 116-gene signature set was also used to compare N þ to NÀ primary tumors using two-dimensional principal-components analysis. The principal-components analysis reduces the information in the individual genes into linear combinations of the gene transcript signals and is commonly used to visualize differences among groups of samples (Butte, 2002) . This analysis readily distinguished the primary tumors with metastasis from those without, again with patient 16 positioned between the two groups. The signature gene set was compared with gene sets of an equal number of randomly selected genes that failed to discriminate between the tumor groups ( Figure 3 ).
We hypothesized that lymph node metastases from the metastatic patients would associate with the N þ group, since the metastases were derived from N þ tumors. Using principal-components analysis with the signature gene set, all lymph node metastases clearly clustered with the N þ group (Figure 4) .
We tested the ability of the principal-components analysis to predict lymph node metastasis by evaluating an independent test set of four patients. Three patients presented with OSCC (two metastatic, one nonmetastatic), and one presented with metastatic cancer of the larynx. Using principal-components analysis, all metastatic tumors from the test set clearly associated with the N þ from the initial data set, but the nonmetastatic tumor from the test set was not clearly classified with either group (Figure 4) .
Unlike principal-components analysis, which reduces the dimensionality of the data, support vector machines (SVMs) use kernel functions to increase the number of dimensions in order to better separate two groups of data (Butte, 2002) . The machine searches for a hyperplane in multidimensional space that is maximally distant from both groups, then reclassifies all samples based upon their orientation to the hyperplane. The vectors, which map the position of each sample in multidimensional space, are summed to yield the discriminant score, which is used to classify the sample into one of two groups. The leave-one-out analysis employs multiple permutations of the data to determine the hyperplane, at each iteration removing a different training (original patient set) sample. Using this approach, all lymph node metastases were classified with the N þ group, all patients from the test set were classified with the appropriate groups, and patient 16, who had not been clearly classified using hierarchical clustering or principalcomponents analysis, was classified correctly (Figure 5b ). Because we used the 116-gene set chosen by SAM as our input to the SVM, our classification using the leave-one-out approach may be overly optimistic. To ensure that our results were not an artifact of the analysis, we used the SVM to predict the tumor classes using sets of an equal number of randomly chosen, above-threshold genes. These random gene sets were consistently unable to discriminate between N þ and NÀ groups (Figure 5a) .
None of the genes in our signature set have been previously associated with lymph node metastasis in HNSCC, although different experimental methods have implicated some in squamous cell cancer (TDRD1 (Loriot et al., 2003) , transglutaminase 3 (Chen et al., 2000), ERBB4 (Bei et al., 2001) , keratin 13 (Depondt et al., 1999) ) and correlated others with aggressiveness and invasiveness of a diverse group of primary tumors (ERBB4 and keratin 13, OSCC (Depondt et al., 1999; Bei et al., 2001) ; KLF12, melanoma (Karjalainen et al., 1998; Roth et al., 2000) ; ATP6V1C1, pancreatic (Ohta et al., 1996) ; KCNJ5, breast (Kennedy et al., 1999; Stringer et al., 2001) ). Unexpectedly CXCR4, which has been previously correlated with metastasis in HNSCC as well as other tumor types, did not emerge in our list of differentially expressed genes (Uchida et al., 2003; Delilbasi et al., 2004) . To evaluate CXCR4 expression in these patients, we examined RNA and protein levels by quantitative RT-PCR and immunohistochemistry, but found no significant differences in CXCR4 cytoplasmic or nuclear expression among N þ , NÀ, or lymph node metastases (Figure 6a-c) , consistent with the Affymetrix data. In contrast with CXCR4, immunohistochemistry revealed the differential expression of Col2 between N þ and NÀ patient groups, consistent with its differential expression at the RNA level (Figure 6d ). 
Discussion
These results demonstrate that measurable differences in gene expression exist between N þ and NÀ primary tumors and that these differences are sufficient to predict the N status of an independent set of patients using a leave-one-out crossvalidation approach. Despite the relatively small sample size, significance was high. The relevance of our results is supported by the correct prediction of an independent test set. Although the test set is small, it is extremely important since independent validation is very rare in microarray studies (Ntzani and Ioannidis, 2003) . These results are consistent with the ability of gene signatures developed from studies in hematogenous metastasis systems to predict overall prognosis based on the gene expression of the primary tumor van't Veer et al., 2002; Ramaswamy et al., 2003) . We evaluated several methods for discriminating between N þ and NÀ tumors. Hierarchical clustering, although commonly used, suffers from a lack of robustness, statistical instability, and variable biological relevance (Clare and King, 2002; Datta and Datta, 2003) , and we used this method strictly as a visualization tool. We generated the signature gene set using a widely accepted statistical method, SAM, that selects genes that are differentially expressed between two groups and estimates a false discovery rate (Tusher et al., 2001 ). Due to the wide variation in published gene signatures even pertaining to the relatively narrow question of transformation in HNSCC, we considered the accurate prediction of an independent validation set essential to evaluating our results (Alevizos et al., 2001; Mendez et al., 2002; Gonzalez et al., 2003; Hwang et al., 2003; Leethanakul et al., 2003; Ntzani and Ioannidis, 2003) . Principal-components analysis is also a useful visual tool but is not considered a robust predictor, and in our hands showed a trend differentiating NÀ from N þ . We chose to use an SVM as our primary prediction algorithm (Butte, 2002) . SVMs, which predict test cases based upon the expression profiles of the original data set mapped into an expanded dimensional space, have been shown to classify accurately a high percentage of tumors of multiple types in microarray experiments (Furey et al., 2000; Ramaswamy et al., 2001; Butte, 2002) .
Although the differences in gene expression were sufficient for the SVM to classify correctly all the tumors in our study, they do not appear to reveal absolute differences between metastatic and nonmetastatic primary tumors. The visual principal-components analysis suggests a continuum of gene expression similar to that previously shown in lymph node metastasis of breast cancer (West et al., 2001) . Clearly larger studies are warranted to determine boundaries for defining 'clearly metastatic,' 'clearly nonmetastatic,' and 'potentially metastatic' categories.
We chose to embrace the complexity of the tumor system in our experimental design by using nonmicrodissected tissue samples because interactions with Although it is known that keratin 13 is expressed by tumor cells, many of the other genes in the signature could be expressed by tumor or stroma (Depondt et al., 1999) . The presence of immune cells in the primary tumors differed from N þ to NÀ patients, as indicated by differing expression of HLA II DOb and CD64. It is possible that the genetic make-up of the host, through immune or stromal cell interaction with the tumor, may provide a critical step in the progression of a nonmetastatic to a metastatic phenotype. Some of these steps may have been previously identified, since three of the genes in our signature gene set have been previously associated with an aggressive phenotype in other types of cancers. KCNJ5/GIRK4 is a subunit of a G-protein-controlled channel which regulates potassium flow into a cell. Overexpression of its binding partner, GIRK1, was found to be correlated with lymph node metastasis in breast carcinoma (Stringer et al., 2001) . Downregulation of the transcription factor AP-2 is associated with metastasis in melanoma, and our signature gene set includes upregulated KLF12, an AP-2 repressor gene (Karjalainen et al., 1998; Roth et al., 2000) . Vacuolar ATP synthase subunit C, overexpressed in our N þ patients, has been correlated with invasiveness of pancreatic tumors (Ohta et al., 1996) . Our signature gene set also bears some similarities with the one defined for lymph node metastasis of pancreatic tumors by Nakamura et al. (2004) (DLG3, Smad6, and AP1S1 compared with DLG5, Smad3, and AP3D1), perhaps indicating the presence of common pathways promoting lymphatic metastasis in different types of tumors.
One gene we were surprised to find missing from our signature set was CXCR4, a chemokine receptor that is being investigated as a regulator of metastasis. Although immunohistochemical studies in HNSCC, melanoma, and breast cancer have suggested a role for CXCR4 in lymph node metastasis, our examination found no correlation between CXCR4 expression and metastasis either in differentiating N þ from NÀ or N þ from lymph node metastasis (Robledo et al., 2001; Kato et al., 2003; Uchida et al., 2003; Delilbasi et al., 2004) . Experiments in mice which inserted CXCR4 into metastatic cells resulted in an increase in hematogenous metastasis only, and blockade of CXCR4/SDF-1 interaction has a much greater inhibitory effect on hematogenous than lymphatic metastasis (Muller et al., 2001; Murakami et al., 2002) . Recent data show that CXCR4 is able to enhance T-cell entrance to the lymph node via the bloodstream but not the lymphatics (Scimone et al., 2004) . Therefore, we propose that CXCR4's role in 
Array hybridization and data analysis
Probes were generated using the procedures described by Affymetrix (Santa Clara, CA, USA) by the University of Pennsylvania Microarray Facility and hybridized to an Affymetrix U133A Genechip (Affymetrix, CA, USA). The microarrays were evaluated as described by Affymetrix using a GeneArray 2500 confocal scanner (Affymetrix, CA, USA). The average signal from two sequential scans was calculated for each microarray feature. Background subtraction was carried out using the algorithms provided by Affymetrix Microarray Suite 5.0 (Affymetrix, CA, USA). Total gene expression signal for each array was scaled to 150 signal units to allow comparison of arrays.
Scaled data were imported into the TIGR Multiexperiment Viewer version 2.2 from the Institute of Genomic Research (Rockville, MD, USA). SAM was used to identify genes differentially expressed between N þ and NÀ samples (Tusher et al., 2001) . Genes whose mean expression levels for both groups fell below background, estimated by the average of Bacillus subtilis gene signals, were discarded. The remaining signature set of genes was analysed using principal-components analysis (scaled for equal variance, results extracted by JScatter, a lab-based program, for visualization) and SVM. Crossvalidation of the original samples using a leave-one-out approach and a diagonal factor of 2 provided an estimate of the accuracy of the SVM algorithm, which was also used to predict the classes of four independent samples.
Quantitative RT-PCR
Real-time RT-PCR primers and probes were designed using ABI Primer Express (Applied Biosystems, Foster City, CA, USA), manufactured by Integrated DNA Technologies Inc. (Coralville, IA, USA), and analysed in the University of Pennsylvania Center for AIDS Research ABI Prism 7700 Sequence Detection System (Applied Biosystems, CA, USA). Samples were quantitated according to the ÀDDC T method (Livak and Schmittgen, 2001 ).
Immunohistochemistry
Formalin-fixed, paraffin-embedded sections of patient tissues were dewaxed according to standard procedures and blocked in 2% H 2 O 2 in methanol at room temperature for 20 min. CXCR4 staining included incubation in 10 mM sodium citrate at pH 6.0 for 5 min at 951C, blocking with 10% goat serum at 371C for 1 h, and overnight incubation at 41C with antibody (12G5, R&D Systems, Minneapolis, MN, USA) at 1 : 400 dilution. Col2 staining included incubation with pepsin (Abcam, Cambridge, MA, USA) at 371C for 30 min and 1 h incubation at 371C with antibody (6B3, Chemicon, Temecula, CA, USA) at 1 : 25 dilution.
